Full Press Release Details
Aditxt Signs Amendment to Extend Worldwide Licensing
Agreement, Granting Exclusivity in all Fields of Use
The amendment expands AditxtScore's clinical
utility for personalizing the selection of the right
treatment for individuals and monitoring their response to the treatment
VA - December 29, 2021 - Aditxt, Inc. ("Aditxt"
or the "Company") (Nasdaq: ADTX), a biotech innovation company
with a mission to improve the health of the immune system, today announced it had signed an amendment to its February 3, 2020, Exclusive
License Agreement with Stanford University, extending Aditxt's exclusive right to license the technology deployed in AditxtScore
and securing worldwide exclusivity in all fields of use of the licensed technology (the "Technology").
The Technology is a highly sensitive and accurate
method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of clinical and
commercial opportunities. The Technology underpins the AditxtScore platform, allowing for a standardization of cellular assays.
These assays can then be used as a development platform for clinical utility. Applications of the Technology can be used to profile individuals
to select appropriate therapies and assess immune status before, during, and after therapeutic intervention.
are grateful for this continued and expanded license to apply this Technology to additional fields including organ transplantation, disease
detection, drug development, and vaccine design," stated Amro Albanna, Co-Founder and CEO of Aditxt. "Less
than one year ago, we signed this strategic exclusive licensing agreement. Since then, we have advanced the development of the Technology,
established our AditxtScore Immune Monitoring Center in Richmond, VA, secured CLIA and CAP accreditation, and became Medicare licensed," Albanna
Aditxt develops technologies focused on improving
immune system health through immune monitoring and reprogramming. Aditxt's
immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile. Aditxt's
immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection
of transplanted organs, autoimmune diseases, and allergies. AditxtScore for COVID-19 is Aditxt's
proprietary immune profile technology to equip people with information about their level of protection. For more information, please visit:
www.aditxt.com and www.AditxtScore .com
Forward-Looking Statements
in this press release constitute "forward-looking statements"
within the meaning of federal securities laws. All statements other than historical fact contained in this press release, including, without
limitation, those regarding the execution of a definitive agreement with the target company and the terms thereof, the completion of the
acquisition and its expected benefits, and statements regarding the Company's
intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's
ongoing and planned product and business development; the Company's
intellectual property position; the Company's ability to develop
commercial functions; expectations regarding product launch and revenue; the Company's
results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the
Company operates; and the trends that may affect the industry or the Company, are forward-looking statements. Forward-looking statements
are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements
as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk
Factors" in the Company's most recent Annual Report on Form
10-K, as well as discussions of potential risks, uncertainties, and other essential factors in the Company's
other filings with the Securities and Exchange Commission. All such statements speak only as of the date made. The Company undertakes
no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contact: